Cargando…
P017 Echinocandin resistance mechanism in Candida tropicalis and Candida glabrata
POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM: OBJECTIVE: Candida tropicalis and Candida glabrata account for 41.6% and 7.08% of total Candidaemia cases in India. Echinocandins are the first-line treatment option for these infections. Resistance to Echinocandins is rare with Candida sp....
Autores principales: | Sharma, Dipti, Paul, Raees A, Murlidharan, Jayashree, Sharma, Sadhna, Kaur, Harsimran, Ghosh, Anup K, Chakrabarti, Arunaloke, Rudramurthy, Shivaprakash M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509966/ http://dx.doi.org/10.1093/mmy/myac072.P017 |
Ejemplares similares
-
P373 Does biofilm forming capacity of Candida tropicalis vary with echinocandin susceptibility?
por: Ritika,, et al.
Publicado: (2022) -
P015 A study to demonstrate heteroresistance and tolerance to azoles in Candida tropicalis
por: Reddy, Snigdha, et al.
Publicado: (2022) -
S5.1d Mechanisms of azole antifungal resistance in clinical isolates of Candida tropicalis
por: Ghosh, Anup, et al.
Publicado: (2022) -
P018 Susceptibility profile of Candida albicans causing bloodstream infections against azole antifungals over 5 years: A prospective observational study
por: Sharma, Megha, et al.
Publicado: (2022) -
P005 Competitive fitness and trade-offs associated with azole resistance in Candida auris clinical isolates
por: Das, Sourav, et al.
Publicado: (2022)